pioglitazone has been researched along with Bone Loss, Osteoclastic in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 9.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 5.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| "The highest doses of rosiglitazone (10 mg/kg/day) or pioglitazone (30 mg/kg/day) were required to reduce fever peaks associated with acute or chronic inflammation, respectively, and to decrease arthritis severity." | 3.74 | Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. ( Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Muresan, M; Netter, P; Sebillaud, S; Weryha, G, 2008) |
| "Vildagliptin treatment significantly increased BMD and trabecular bone volume." | 1.43 | Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats. ( Eom, YS; Gwon, AR; Kim, BJ; Kim, JY; Kim, KW; Kim, YS; Kwak, KM; Lee, K; Lee, S; Park, IB; Yu, SH, 2016) |
| "Pioglitazone treatment led to reduction of the bone formation marker osteocalcin, whereas balaglitazone treatment did not affect it." | 1.35 | A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. ( Beck-Nielsen, H; Byrjalsen, I; Christiansen, C; Henriksen, K; Karsdal, MA; Larsen, LK; Madsen, AN; Nielsen, RH, 2009) |
| "Thus, TZDs may suppress bone resorption in diabetic patients and prevent bone loss." | 1.30 | Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. ( Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanda, J | 1 |
| Izumo, N | 1 |
| Kobayashi, Y | 1 |
| Onodera, K | 1 |
| Shimakura, T | 1 |
| Yamamoto, N | 1 |
| Takahashi, HE | 1 |
| Wakabayashi, H | 1 |
| Bone, HG | 1 |
| Lindsay, R | 1 |
| McClung, MR | 1 |
| Perez, AT | 1 |
| Raanan, MG | 1 |
| Spanheimer, RG | 1 |
| Xu, F | 1 |
| Dong, Y | 1 |
| Huang, X | 1 |
| Chen, P | 1 |
| Guo, F | 1 |
| Chen, A | 1 |
| Huang, S | 1 |
| Eom, YS | 1 |
| Gwon, AR | 1 |
| Kwak, KM | 1 |
| Kim, JY | 1 |
| Yu, SH | 1 |
| Lee, S | 1 |
| Kim, YS | 1 |
| Park, IB | 1 |
| Kim, KW | 1 |
| Lee, K | 1 |
| Kim, BJ | 1 |
| Debiais, F | 1 |
| Henriksen, K | 1 |
| Byrjalsen, I | 1 |
| Nielsen, RH | 1 |
| Madsen, AN | 1 |
| Larsen, LK | 1 |
| Christiansen, C | 1 |
| Beck-Nielsen, H | 1 |
| Karsdal, MA | 1 |
| Samadfam, R | 1 |
| Awori, M | 1 |
| Bénardeau, A | 1 |
| Bauss, F | 1 |
| Sebokova, E | 1 |
| Wright, M | 1 |
| Smith, SY | 1 |
| Tsirella, E | 1 |
| Mavrakanas, T | 1 |
| Rager, O | 1 |
| Tsartsalis, S | 1 |
| Kallaras, K | 1 |
| Kokkas, B | 1 |
| Mironidou-Tzouveleki, M | 1 |
| Koufany, M | 1 |
| Moulin, D | 1 |
| Bianchi, A | 1 |
| Muresan, M | 1 |
| Sebillaud, S | 1 |
| Netter, P | 1 |
| Weryha, G | 1 |
| Jouzeau, JY | 1 |
| Okazaki, R | 1 |
| Toriumi, M | 1 |
| Fukumoto, S | 1 |
| Miyamoto, M | 1 |
| Fujita, T | 1 |
| Tanaka, K | 1 |
| Takeuchi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment[NCT00708175] | Phase 4 | 156 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 1 |
| Placebo | 3 |
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Baseline and Month 12.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.69 |
| Placebo | -0.14 |
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Month 12 and Month 18.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.14 |
| Placebo | 0.04 |
The change between the fasting plasma glucose value collected at each time frame indicated. (NCT00708175)
Timeframe: Baseline and Month 12; Month 12 and Month 18.
| Intervention | mg/dL (Least Squares Mean) | |
|---|---|---|
| Baseline to Month 12 (n=57; n=61) | Month 12 to Month 18 (n=54; n=57) | |
| Pioglitazone | -2.8 | 0.4 |
| Placebo | 6.0 | -1.0 |
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) | |
|---|---|---|
| Double-Blind Period (n=76; n=75) | Follow-up Period (n=63; n=59) | |
| Pioglitazone | 1 | 0 |
| Placebo | 7 | 1 |
1 trial available for pioglitazone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Topics: Adiposity; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Double- | 2013 |
9 other studies available for pioglitazone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Effect of the antidiabetic agent pioglitazone on bone metabolism in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Resorption; Depression, Chemical; Dose-Response Relation | 2017 |
Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Topics: Animals; Bone Resorption; Cell Communication; Cell Differentiation; Cell Line; Cells, Cultured; Hypo | 2016 |
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
Topics: Adamantane; Animals; Biomarkers; Bone Density; Bone Resorption; Diabetes Mellitus, Experimental; Dia | 2016 |
Thiazolidinediones: antidiabetic agents with effects on bone.
Topics: Aged; Animals; Bone and Bones; Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Disease Mod | 2009 |
A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.
Topics: Adipogenesis; Animals; Biomarkers; Blood Glucose; Body Weight; Bone and Bones; Bone Resorption; Diet | 2009 |
Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Topics: Adiposity; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2012 |
Low dose pioglitazone does not affect bone formation and resorption markers or bone mineral density in streptozocin-induced diabetic rats.
Topics: Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Resorption; Calcium; Collagen Type I; | 2012 |
Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Biomarkers; | 2008 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differen | 1999 |